Back to Search
Start Over
PCSK9 inhibitors and diabetes: Translational biology to clinical practice.
- Source :
-
Diabetes, obesity & metabolism [Diabetes Obes Metab] 2019 Mar; Vol. 21 (3), pp. 451-453. Date of Electronic Publication: 2019 Jan 17. - Publication Year :
- 2019
- Subjects :
- Animals
Antibodies, Monoclonal therapeutic use
Antibodies, Monoclonal, Humanized therapeutic use
Anticholesteremic Agents pharmacology
Cholesterol, LDL blood
Diabetic Angiopathies drug therapy
Diabetic Angiopathies prevention & control
Drug Evaluation, Preclinical methods
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use
Practice Patterns, Physicians' statistics & numerical data
Proprotein Convertase 9 immunology
Randomized Controlled Trials as Topic methods
Anticholesteremic Agents therapeutic use
Clinical Trials as Topic methods
Clinical Trials as Topic statistics & numerical data
Diabetes Mellitus drug therapy
PCSK9 Inhibitors
Practice Patterns, Physicians' trends
Translational Research, Biomedical methods
Translational Research, Biomedical trends
Subjects
Details
- Language :
- English
- ISSN :
- 1463-1326
- Volume :
- 21
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Diabetes, obesity & metabolism
- Publication Type :
- Academic Journal
- Accession number :
- 30520245
- Full Text :
- https://doi.org/10.1111/dom.13600